Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Valeant Pharmaceuticals Intl Inc    VRX   CA91911K1021

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
01/11/2018 01/12/2018 01/15/2018 01/16/2018 01/17/2018 Date
29.81 29.73 30.31 28.6 28.25 Last
2040096 1548033 666146 2374984 2209463 Volume
+1.12% -0.27% +1.95% -5.64% -1.22% Change
Financials ($)
Sales 2017 8 731 M
EBIT 2017 3 316 M
Net income 2017 156 M
Debt 2017 25 448 M
Yield 2017 -
Sales 2018 8 516 M
EBIT 2018 3 076 M
Net income 2018 -903 M
Debt 2018 23 953 M
Yield 2018 -
P/E ratio 2017 4,65
P/E ratio 2018
EV / Sales2017 3,82x
EV / Sales2018 3,74x
Capitalization 7 912 M
More Financials
Company
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.It operates through the following segments: The Bausch +... 
Sector
Pharmaceuticals
Calendar
03/01Earnings Release
More about the company
Surperformance© ratings of Valeant Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on VALEANT PHARMACEUTICALS IN
11:05a VALEANT PHARMACEUTICALS INTL : Bausch + Lomb Receives FDA Approval of LUMIFY - T..
01/17 VALEANT PHARMACEUTICALS INTL INC : Canadian Exchanges Stock Scanner, Valeant Pha..
01/17 Allergan Pact Advances -- WSJ
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 VALEANT PHARMACEUTICALS INTL : says California judge gives preliminary approval ..
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 VALEANT (VRX) : Onward and Upward
01/15 VALEANT PHARMACEUTICALS INTL : Ortho Dermatologics Announces U.S. FDA Filing Acc..
01/12 VALEANT PHARMACEUTICALS INTL : CEO Is in the Midst of the ‘Turnaround Oppo..
01/12 Respiratory Syncytial Virus Infections– Unmet Needs in Adult Targeted D..
More news
Sector news : Pharmaceuticals - NEC
10:12a Wall Street slips as healthcare, energy stocks drag
07:38a ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
06:27a BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's ..
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
More sector news : Pharmaceuticals - NEC
Latest Tweets
04:33pHC Wainwright Increases Valeant Pharmaceuticals Intl $VRX Price Target to $24.. 
01/17Valeant Pharmaceuticals Intl Inc : Canadian Exchanges Stock Scanner, Valeant .. 
01/12Valeant Pharmaceuticals Intl : Ortho Dermatologics Announces U.S. FDA Filing .. 
01/09THIS HOUR on @PowerLunch: $VRX CEO Joe Papa joins @megtirrell LIVE and EXCLUS..
2
01/09NEXT UP from #JPM18 on @CNBC: $VRX CEO Joe Papa joins @megtirrell LIVE and EX..
1
More tweets
Qtime:128
News from SeekingAlpha
10:34a Big Biopharma in the red in early trade
10:06a Generic firms under pressure on possible hospital drug-making venture
08:21a Hospital groups planning to enter generic drugs business
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/14 WORST YEAR EVER : Bill Ackman Or Eddie Lampert?
Chart VALEANT PHARMACEUTICALS IN
Duration : Period :
Valeant Pharmaceuticals In Technical Analysis Chart | VRX | CA91911K1021 | 4-Traders
Technical analysis trends VALEANT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 16,4 $
Spread / Average Target -28%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive VP-Finance
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALEANT PHARMACEUTICALS INTL INC7.50%8 011
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287